NCTR Research Highlights

NCTR Research Highlights
-----------------------
Current Highlight from July 24, 2009
-----------------------
Human Cancer Risk from Dietary Acrylamide
The results from National Center for Toxicological Research (NCTR) cancer bioassays for acrylamide and its mutagenic metabolite, glycidamide, were presented at the 32nd Annual Meeting of the United Kingdom Environmental Mutagen Society held July 12-15, 2009 in Leeds.

The results of the two-year drinking water studies with rats and mice, and the neonatal mouse assay, strongly supported the crucial role of glycidamide in directly mutagenizing (causing mutation of) DNA as the mechanism of action (MOA) for acrylamide's ability to cause tumors.
Further support for the conclusions of the tumor studies was obtained from the isolation and characterization of glycidamide-DNA and glycidamide-hemoglobin adducts in the same models.

Acrylamide is a contaminant in baked and fried starchy foods (e.g., french fries, potato chips, and bread) and is present in coffee, Postum (coffee substitute), olives, and certain breakfast cereals. Acrylamide causes cancer in laboratory animals, and the data from NCTR's recent research will help resolve the controversy regarding its MOA, which is crucial for the evaluation of cancer risks in humans from dietary exposures. NCTR's fully peer-reviewed Good Laboratory Practices studies will be presented to NCTR's IAG partner, National Toxicology Program/National Institute of Environmental Health Sciences.

For more information, contact Dr. Fred Beland, Director, Division of Biochemical Toxicology, NCTR, or Dr. William Slikker, Jr., Director, NCTR.

abrir aquí para acceder al documento FDA:
NCTR Research Highlights